Insmed Incorporated
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company founded in 1988 and headquartered in Bridgewater, New Jersey, focuses on rare diseases with investigational and approved therapies in pulmonary, inflammatory, and other serious conditions; its approved products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease in adults with limited treatment options and BRINSUPRI (brensocatib), a first-in-class neutrophil elastase inhibitor for non-cystic fibrosis bronchiectasis; the company advances a pipeline encompassing TPIP for pulmonary arterial hypertension, INS1201, and preclinical programs in gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, serving patients primarily through clinical trials and commercial launches targeting chronic lung diseases. Insmed operates 9 corporate offices and 4 global research sites across the United States, Europe, Japan, and other regions, with over 1,500 employees as of mid-2025. Recent developments include FDA approval of BRINSUPRI in 2025 and its subsequent European Union approval, topline results from the Phase 2b pulmonary arterial hypertension study and Phase 3 ASPEN study in 2024-2025, the opening of a new research lab in Cambridge, UK, a proposed $650 million public offering of common stock in June 2025, raised full-year 2025 ARIKAYCE revenue guidance to $420-430 million, and repeated recognition as the No. 1 biopharma employer by Science magazine.
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
Insmed: Extensive Phase 3 TPIP Program And Revenue Growth In Q1 2026, Strong Buy
Nasdaq-100 Index® June 2026 Quarterly Changes
Insmed Incorporated (INSM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed to Present at May 2026 Investor Conferences
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026